CVR: 32289290
Secondary names: VPN ApS, XGX ApS, XGX-Pharma ApS
DKK 32,338,381
Gross profit
Net result: DKK 16,074,119
Unimedic Pharma AB
CVR · view ownership and management
Owner registered: Unimedic Pharma AB
CVR · 21/07/2025
View the full event history
XGX Pharma ApS is a Danish company of the type Anpartsselskab based in København K, founded in 2009. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The management consists of Jens-Nikolaj Schøier. The company is owned by Unimedic Pharma AB. The company has 2 employees (2018). In 2025, the company reported a gross profit of DKK 32,338,381 and a net result of DKK 16,074,119 compared with DKK 4,453,433 the year before. Equity in the 2025 report amounted to DKK 30,787,180.
Source: annual report 2025, Danish Business Authority
XGX Pharma ApS demonstrates a strong upward trajectory in profitability, with gross profit increasing from 2.9 million DKK in 2022 to 32.3 million DKK in 2025, alongside a significant rise in profit from a loss of 1.8 million DKK in 2022 to 16.1 million DKK in 2025. The company's equity has also improved markedly, reaching 30.8 million DKK in 2025, indicating a solid financial foundation. However, the absence of revenue figures raises concerns about transparency and operational scale within the pharmaceutical wholesale industry. Overall, XGX Pharma appears well-positioned for growth, bolstered by strong margins and a healthy equity position.
AI-generated summary · Generated 16/08/2026
Selskabets formål er at drive virksomhed med fremstilling, markedsføring og distribution af medicinske produkter samt at udøve enhver aktivitet, der efter ledelsens skøn er forbundet hermed.
Source: annual reports filed with the Danish Business Authority.
| Period | Gross Profit | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 202501/01/2025 – 31/12/2025 | 32.3 mio. | 16.1 mio. | 55.1 mio. | 30.8 mio. | 0 | |
| 202401/01/2024 – 31/12/2024 | 16 mio. | 4.5 mio. | 39 mio. | 18.7 mio. | 4 | |
| 202301/01/2023 – 31/12/2023 | 8.1 mio. | 461 t. | 29.6 mio. | 14.3 mio. | 5 | |
| 202201/01/2022 – 31/12/2022 | 2.9 mio. | -1.8 mio. | 27.6 mio. | 13.8 mio. | 4 | |
| 202101/01/2021 – 31/12/2021 | 14.5 mio. | 7.2 mio. | 21.3 mio. | 13.2 mio. | 3 | |
| 202001/01/2020 – 31/12/2020 | 15.2 mio. | 6 mio. | 24.9 mio. | 12.9 mio. | 3 | |
| 201901/01/2019 – 31/12/2019 | 11.7 mio. | 8.4 mio. | 18.8 mio. | 11.4 mio. | 3 | |
| 201801/01/2018 – 31/12/2018 | 1.6 mio. | 27 t. | 3.5 mio. | 59 t. | 1 | |
| 201701/01/2017 – 31/12/2017 | 104 t. | -189 t. | 1.3 mio. | 32 t. | - | |
| 201601/01/2016 – 31/12/2016 | 307 t. | 272 t. | 877 t. | 92 t. | - | |
| 201501/01/2015 – 31/12/2015 | -33 t. | -35 t. | 900 t. | -180 t. | - | |
| 201401/01/2014 – 31/12/2014 | - | -14 t. | 466 t. | -145 t. | - | |
| 201301/01/2013 – 31/12/2013 | 145 t. | 145 t. | 14 t. | 130 t. | - | |
| 201201/01/2012 – 31/12/2012 | 84 t. | 96 t. | 66 t. | -14 t. | - |
Compared to 407 companies in Engroshandel med medicinalvarer og sygeplejeartikler
Comparison is based on industry median values
Screen owners and management against the Danish FSA's official PEP lists
7 public tenders won
Sources: TED (the EU tender database) and udbud.dk
Build lead lists with filters on industry, geography, size and financials — and export straight to Excel.
Try the lead list generatorXGX Pharma ApS was founded on 14 July 2009.
XGX Pharma ApS is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler (industry code 464610).
XGX Pharma ApS had 2 employees in 2018 according to the Danish CVR register.
XGX Pharma ApS is owned by Unimedic Pharma AB.
In 2025, XGX Pharma ApS reported a gross profit of DKK 32,338,381.
The management of XGX Pharma ApS consists of Jens-Nikolaj Schøier.
Claim this page to add your logo and social links. Free to get started.
XGX Pharma ApS has published its annual report for 2025. Gross profit came to DKK 32,338,381, and the net result was DKK 16,074,119.
XGX Pharma ApS has won the tender "Amgros 2026 1.1216.a" issued by Amgros I/S worth 19,794,473 DKK.
XGX Pharma ApS has won the tender "Amgros 2026 1.1202.a" issued by Amgros I/S worth 383,606,720 DKK.
XGX Pharma ApS has won the tender "Amgros 2026 1.604.a" issued by Amgros I/S worth 501,367,776 DKK.
XGX Pharma ApS has won the tender "Amgros 2026 1.201.a" issued by Amgros I/S worth 286,787,957 DKK.
As of July 21, 2025, KPMG P/S has been appointed auditor of XGX Pharma ApS.
As of July 21, 2025, Kreston CM Statsautoriseret Revisions interessentskab has stepped down as auditor of XGX Pharma ApS.
As of July 21, 2025, Per Anders Larnholt has joined the board of directors of XGX Pharma ApS.
As of July 21, 2025, Johan Frödin has joined the board of directors of XGX Pharma ApS.
As of July 21, 2025, Mohammad Sohail Asghar has left the board of directors of XGX Pharma ApS.
As of July 21, 2025, Lars Karlsmose has left the board of directors of XGX Pharma ApS.
As of July 21, 2025, Jens-Nikolaj Schøier has left the board of directors of XGX Pharma ApS.
As of July 21, 2025, is registered as an owner of XGX Pharma ApS with an ownership share of 100%.
XGX Pharma ApS has published its annual report for 2024. Gross profit came to DKK 16,033,793, and the net result was DKK 4,453,433.
XGX Pharma ApS has won the tender "Amgros 2025 1.206.a" issued by Amgros I/S worth 9,418,664 DKK.
XGX Pharma ApS has won the tender "Amgros 2025 2.1310.b" issued by Amgros I/S worth 129,999,998 DKK.
XGX Pharma ApS has won the tender "Amgros 2025 1.1202.a" issued by Amgros I/S worth 90,124,932 DKK.
XGX Pharma ApS has published its annual report for 2023. Gross profit came to DKK 8,100,823, and the net result was DKK 460,891.
XGX Pharma ApS has published its annual report for 2022. Gross profit came to DKK 2,917,678, and the net result was DKK -1,842,554.
XGX Pharma ApS has published its annual report for 2021. Gross profit came to DKK 14,515,287, and the net result was DKK 7,248,505.
As of May 10, 2022, Mohammad Sohail Asghar has joined the board of directors of XGX Pharma ApS.
As of May 10, 2022, Rolf Eckersberg has left the board of directors of XGX Pharma ApS.
As of May 9, 2022, Mohammad Sohail Asghar has left the board of directors of XGX Pharma ApS.
XGX Pharma ApS has published its annual report for 2020. Gross profit came to DKK 15,225,623, and the net result was DKK 6,004,347.
XGX Pharma ApS has published its annual report for 2019. Gross profit came to DKK 11,716,951, and the net result was DKK 8,356,668.
As of February 14, 2020, Kreston CM Statsautoriseret Revisions interessentskab has been appointed auditor of XGX Pharma ApS.
As of February 14, 2020, PRICEWATERHOUSECOOPERS STATSAUTORISERET REVISIONSPARTNERSELSKAB has stepped down as auditor of XGX Pharma ApS.
As of January 27, 2020, Rolf Eckersberg has joined the board of directors of XGX Pharma ApS.
As of January 27, 2020, Per Ludvigsen has left the board of directors of XGX Pharma ApS.
As of November 22, 2019, Lars Karlsmose has joined the board of directors of XGX Pharma ApS.
XGX Pharma ApS has published its annual report for 2018. Gross profit came to DKK 1,574,797, and the net result was DKK 26,878.
As of November 1, 2018, Mohammad Sohail Asghar has joined the board of directors of XGX Pharma ApS.
As of November 1, 2018, Per Ludvigsen has joined the board of directors of XGX Pharma ApS.
As of November 1, 2018, Jens-Nikolaj Schøier has joined the board of directors of XGX Pharma ApS.
XGX Pharma ApS has published its annual report for 2017. Gross profit came to DKK 104,432, and the net result was DKK -189,057.
As of December 1, 2017, PRICEWATERHOUSECOOPERS STATSAUTORISERET REVISIONSPARTNERSELSKAB has been appointed auditor of XGX Pharma ApS.
As of December 1, 2017, Jens-Nikolaj Schøier is registered as adm. dir. of XGX Pharma ApS.
As of December 1, 2017, Mohammad Sohail Asghar has stepped down as director of XGX Pharma ApS.
XGX Pharma ApS has published its annual report for 2016. Gross profit came to DKK 307,092, and the net result was DKK 271,902.
XGX Pharma ApS has published its annual report for 2015. Gross profit came to DKK -32,643, and the net result was DKK -34,858.
XGX Pharma ApS has published its annual report for 2014. The net result was DKK -14,436.
As of June 23, 2015, REVISIONSFIRMAET WOIREMOSE & PARTNER REGISTRERET REVISIONSANPARTSSELSKAB has stepped down as auditor of XGX Pharma ApS.
As of May 15, 2015, REVISIONSFIRMAET WOIREMOSE & PARTNER REGISTRERET REVISIONSANPARTSSELSKAB has been appointed auditor of XGX Pharma ApS.
As of May 15, 2015, Kreston CM Statsautoriseret Revisions interessentskab has stepped down as auditor of XGX Pharma ApS.
XGX Pharma ApS has published its annual report for 2013. Gross profit came to DKK 144,613, and the net result was DKK 144,707.
XGX Pharma ApS has published its annual report for 2012. Gross profit came to DKK 83,774, and the net result was DKK 96,450.
As of July 14, 2009, Kreston CM Statsautoriseret Revisions interessentskab has been appointed auditor of XGX Pharma ApS.
As of July 14, 2009, Mohammad Sohail Asghar is registered as director of XGX Pharma ApS.
XGX Pharma ApS was founded on July 14, 2009.
Companies in the same industry and area
CVR 35451307
CVR 19835081
CVR 21327581
CVR 46124723
CVR 19064301
